These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21620714)

  • 1. Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.
    Shukla NM; Malladi SS; Day V; David SA
    Bioorg Med Chem; 2011 Jun; 19(12):3801-11. PubMed ID: 21620714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors
    Padilla-Salinas R; Anderson R; Sakaniwa K; Zhang S; Nordeen P; Lu C; Shimizu T; Yin H
    J Med Chem; 2019 Nov; 62(22):10221-10244. PubMed ID: 31687820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.
    Shukla NM; Mutz CA; Malladi SS; Warshakoon HJ; Balakrishna R; David SA
    J Med Chem; 2012 Feb; 55(3):1106-16. PubMed ID: 22239408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs.
    Yang M; Larson PG; Brown L; Schultz JR; Kucaba TA; Griffith TS; Ferguson DM
    Bioorg Med Chem Lett; 2022 Mar; 59():128548. PubMed ID: 35051578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline.
    Shukla NM; Kimbrell MR; Malladi SS; David SA
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2211-4. PubMed ID: 19285861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.
    Gorden KK; Qiu X; Battiste JJ; Wightman PP; Vasilakos JP; Alkan SS
    J Immunol; 2006 Dec; 177(11):8164-70. PubMed ID: 17114492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds.
    Dolšak A; Švajger U; Lešnik S; Konc J; Gobec S; Sova M
    Eur J Med Chem; 2019 Oct; 179():109-122. PubMed ID: 31247373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity.
    Vlach J; Bender AT; Przetak M; Pereira A; Deshpande A; Johnson TL; Reissig S; Tzvetkov E; Musil D; Morse NT; Haselmayer P; Zimmerli SC; Okitsu SL; Walsky RL; Sherer B
    J Pharmacol Exp Ther; 2021 Mar; 376(3):397-409. PubMed ID: 33328334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
    Hunt JR; Kleindl PA; Moulder KR; Prisinzano TE; Forrest ML
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126788. PubMed ID: 31784317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues.
    Shukla NM; Malladi SS; Mutz CA; Balakrishna R; David SA
    J Med Chem; 2010 Jun; 53(11):4450-65. PubMed ID: 20481492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.
    Knoepfel T; Nimsgern P; Jacquier S; Bourrel M; Vangrevelinghe E; Glatthar R; Behnke D; Alper PB; Michellys PY; Deane J; Junt T; Zipfel G; Limonta S; Hawtin S; Andre C; Boulay T; Loetscher P; Faller M; Blank J; Feifel R; Betschart C
    J Med Chem; 2020 Aug; 63(15):8276-8295. PubMed ID: 32786235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of TLR7/8 small RNA antagonists.
    Sioud M
    Methods Mol Biol; 2010; 629():387-94. PubMed ID: 20387163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes.
    Ganapathi L; Van Haren S; Dowling DJ; Bergelson I; Shukla NM; Malladi SS; Balakrishna R; Tanji H; Ohto U; Shimizu T; David SA; Levy O
    PLoS One; 2015; 10(8):e0134640. PubMed ID: 26274907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule inhibition of TLR8 through stabilization of its resting state.
    Zhang S; Hu Z; Tanji H; Jiang S; Das N; Li J; Sakaniwa K; Jin J; Bian Y; Ohto U; Shimizu T; Yin H
    Nat Chem Biol; 2018 Jan; 14(1):58-64. PubMed ID: 29155428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides.
    Jurk M; Kritzler A; Schulte B; Tluk S; Schetter C; Krieg AM; Vollmer J
    Eur J Immunol; 2006 Jul; 36(7):1815-26. PubMed ID: 16783850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Molecule TLR8 Antagonists via Structure-Based Rational Design.
    Hu Z; Tanji H; Jiang S; Zhang S; Koo K; Chan J; Sakaniwa K; Ohto U; Candia A; Shimizu T; Yin H
    Cell Chem Biol; 2018 Oct; 25(10):1286-1291.e3. PubMed ID: 30100350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of a novel chemotype for human TLR8 inhibitors.
    Šribar D; Grabowski M; Murgueitio MS; Bermudez M; Weindl G; Wolber G
    Eur J Med Chem; 2019 Oct; 179():744-752. PubMed ID: 31284084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA and imidazoquinolines are sensed by distinct TLR7/8 ectodomain sites resulting in functionally disparate signaling events.
    Colak E; Leslie A; Zausmer K; Khatamzas E; Kubarenko AV; Pichulik T; Klimosch SN; Mayer A; Siggs O; Hector A; Fischer R; Klesser B; Rautanen A; Frank M; Hill AV; Manoury B; Beutler B; Hartl D; Simmons A; Weber AN
    J Immunol; 2014 Jun; 192(12):5963-73. PubMed ID: 24813206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and validation of a novel dual small-molecule TLR2/8 antagonist.
    Grabowski M; Bermudez M; Rudolf T; Šribar D; Varga P; Murgueitio MS; Wolber G; Rademann J; Weindl G
    Biochem Pharmacol; 2020 Jul; 177():113957. PubMed ID: 32268138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.
    Alper PB; Deane J; Betschart C; Buffet D; Collignon Zipfel G; Gordon P; Hampton J; Hawtin S; Ibanez M; Jiang T; Junt T; Knoepfel T; Liu B; Maginnis J; McKeever U; Michellys PY; Mutnick D; Nayak B; Niwa S; Richmond W; Rush JS; Syka P; Zhang Y; Zhu X
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127366. PubMed ID: 32738975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.